Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents

Journal of Neural Transmission

Volumn 114, Issue 2, 2007, Pages 273-280

  Fleischhaker, C ^a   Heiser, P ^b   Hennighausen, K ^a   Herpertz Dahlmann, B ^c   Holtkamp, K ^c   Mehler Wex, C ^d   Rauh, R ^a   Remschmidt, H ^b   Schulz, E ^a   Warnke, A ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Adolescents; Atypical antipsychotics; Weight gain

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; CHLORPROTHIXENE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LACTULOSE; LEVOMEPROMAZINE; LORAZEPAM; METIXENE; METOCLOPRAMIDE; METOPROLOL; OLANZAPINE; PAROXETINE; PERAZINE; PIMOZIDE; PIPAMPERONE; PIRENZEPINE; PROMETHAZINE; RISPERIDONE;

ADOLESCENT; ARTICLE; BODY MASS; BODY WEIGHT; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; CHILD; CLOZAPINE; FEMALE; HUMANS; MALE; MENTAL DISORDERS; RISPERIDONE; WEIGHT GAIN;

EID: 33846420273     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-006-0602-7     Document Type: Article

References (41)

1. DB Allison JL Mentore M Heo LP Chandler JC Cappelleri MC Infante PJ Weiden 1999 Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry 156 1686 1696
2. MG Aman G De Smedt A Derivan B Lyons RL Findling 2002 Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence Am J Psychiatry 159 1337 1346
3. KT Brady 1989 Weight gain associated with psychotropic drugs South Med J 82 611 617
4. JK Buitelaar 2000 Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolecents with mixed diagnoses and aggressive behavior J Child Adolesc Psychopharmacol 10 19 26
5. JK Buitelaar RJ van der Gaag P Cohen-Kettenis CT Melman 2001 A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities J Clin Psychiatry 62 4 239 248
6. Cohen J (1988) Statistical power analysis for the behavioral sciences. Erlbaum, Hillsdale
7. TJ Cole 1990 The LMS method for constructing normalized growth standards Eur J Clin Nutr 44 45 60
8. RL Findling NK McNamara LA Branicky MD Schluchter E Lemon JL Blumer 2000 A double-blind pilot study of risperidone in the treatment of conduct disorder J Am Acad Child Adolesc Psychiatry 39 509 516
9. C Fleischhaker E Schulz H Remschmidt 1998 Biogenic amines as predictors of response to clozapine treatment in early-onset schizophrenia J Psychiatr Res 32 325 333
10. JA Frazier CT Gordon K McKenna MC Lenane D Jih JL Rapaport 1994 An open trial of clozapine adolescents with childhood-onset schizophrenia J Am Acad Child Adolesc Psychiatry 33 658 663
11. D Gothelf A Apter J Reidman A Brand-Gothelf Y Bloch G Gal L Kikinzon S Tyano R Weizman G Ratzoni 2003 Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia J Neural Transm 110 545 560
12. W Guy 1976 ECDEU assessment manual National Institute of Mental Health Rockville, MD
13. R Kant R Chalansani KN Chengappa 2002 The use of clozapine in adolescents with diagnoses other than schizophrenia J Child Adolesc Psychopharmacol 12 290 291
14. A Klimke E Klieser 1995 The atypical neuroleptic clozapine (Leponex) - current knowledge and recent clinical aspects Fortschr Neurol Psychiatr 63 173 193
15. K Kromeyer-Hauschild M Wabitsch D Kunze F Geller HC Geiß V Hesse A von Hippel U Jaeger D Johnsen W Korte K Menner G Müller JM Müller A Niemann-Pilatus T Remer F Schaefer HU Wittchen S Zabransky K Zellner A Ziegler J Hebebrand 2001 Perzentile für den Body-mass-Index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben Monatsschr Kinderheilkde 149 807 818
16. S Kumra JA Frazier LK Jacobsen K McKenna CT Gordon MC Lenane SD Hamburger AK Smith KE Albus J Alaghbandrad JL Rapoport 1996 Childhood-onset schizophrenia - a double-blind clozapine-haloperidol comparison Arch Gen Psychiatry 53 1090 1097
17. S Kumra LK Jacobsen M Lenane BI Karp JA Frazier AK Smith J Bedwell P Lee CJ Malanga S Hamburger JL Rapoport 1998 Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents J Am Acad Child Adolesc Psychiatry 37 377 385
18. R Leadbetter M Shutty D Pavalonis V Vieweg P Higgins M Downs 1992 Clozapine-induced weight gain: prevalence and clinical relevance Am J Psychiatry 149 68 72
19. PJ Lombroso 1996 Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report J Am Acad Child Adolesc Psychiatry 35 394
20. SQ Luo ET Li 1991 Effects of rapid administration of serotonergic agonists on diet selection and body weight in rats Pharmacol Biochem Behav 38 495 500
21. SR Marder SM Essock AL Miller RW Buchanan DE Casey JM Davis JM Kane JA Lieberman NR Schooler N Covell S Stroup EM Weissman DA Wirshing CS Hall L Pogach FX Pi-Sunyer JT Bigger A Friedman D Kleinberg SJ Yevich B Davis LR Shone 2004 Physical health monitoring of patients with schizophrenia Am J Psychiatry 161 1334 1349
22. G Masi A Cosenza M Mucci P Brovedani 2001 Open trial of risperidone in 24 young children with pervasive developmental disorders J Am Acad Child Adolesc Psychiatry 40 1206 1214
23. D Michelson JD Amsterdam FM Quitkin FW Reimherr JF Rosenbaum JM Zajecka KL Sundell Y Kim CM Beasley Jr 1999 Changes in weight during a 1-year trial of fluoxetine Am J Psychiatry 156 1170 1176
24. S Mukherjee P Decina V Bocola F Saraceni PL Scapicchio 1996 Diabetis mellitus in schizophrenic patients Compr Psychiatry 37 68 73
25. DL Murphy C Wichems Q Li 1999 Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission Trends Pharmacol Sci 20 246 252
26. FX Pi-Sunyer 1993 Medical hazards of obesity Ann Intern Med 119 655 660
27. MN Potenza JP Holmes SJ Kanes CJ McDougle 1999 Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study J Clin Psychopharmacol 19 37 44
28. M Prendergast 1992 Drug Treatment Arch Dis Child 67 1488 1494
29. G Ratzoni D Gothelf A Brand-Gothelf J Reidman L Kikinzon G Gal M Phillip A Apter R Weizman 2002 Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study J Am Acad Child Adolesc Psychiatry 41 337 343
30. H Remschmidt K Hennighausen HW Clement P Heiser E Schulz 2000 Atypical neuroleptics in child and adolescent psychiatry Eur Child Adolesc Psychiatry 9 Suppl 1 9 19
31. RA Rison PK Stanton 1995 Long-term potentiation and N-methyl-d-aspartate receptors: foundations of memory and neurologic disease? Neurosci Biobehav Rev 19 533 552
32. WJ Rockwell EH Ellinwood DW Trader 1983 Psychotropic drugs promoting weight gain: health risks and treatment implications South Med J 76 1407 1412
33. RG Ross DK Novins GK Farley LE Adler 2003 A 1-year open-label trial of olanzapine in school-age children with schizophrenia J Child Adolesc Psychopharmacol 13 301 309
34. R Samanin S Garattini 1990 The pharmacology of serotonergic drugs affecting appetite RJ Wurtman JJ Wurtman Nutrition and the brain Raven Press New York 163 192
35. EH Sholevar DA Baron TL Hardie 2000 Treatment of childhood-onset schizophrenia with olanzapine J Child Adolesc Psychopharmacol 10 69 78
36. L Sikich RM Hamer RA Bashford BB Sheitman JA Lieberman 2004 A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial Neuropsychopharmacology 29 133 145
37. LH Tecott LM Sun SF Akana 1995 Eating disorder and epilepsy in mice lacking 5-HT-2c serotonin receptors Nature 374 542 546
38. DA Wirshing 2004 Schizophrenia and obesity: impact of antipsychotic medications J Clin Psychiatry 65 13 26
39. DA Wirshing JA Loyd LR Meng JS Ballon SR Marder WC Wirshing 2002 The effects of novel antipsychotics on glucose and lipid levels J Clin Psychiatry 63 856 865
40. DA Wirshing WC Wirshing L Kysar MA Berisford D Goldstein J Pashdag J Mintz SR Marder 1999 Novel antipsychotics: comparison of weight gain liabilities J Clin Psychiatry 60 358 363
41. G Zalsman H Carnahan A Martin D Bensason A Weizman S Tyano 2003 Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-lebel study J Child Adolesc Psychopharmacol 13 327